An extension to the company’s Series A brings total funding to €23 million and clears the path for the first human trial of KUP101, a dual TLR agonist targeting solid tumours and drug-resistant infections. Most immunotherapy research in oncology has concentrated on the adaptive immune system, the le
⚡Key InsightsAI analyzing…
A
Ana-Maria Stanciuc
📡
Original Source
The Next Web
https://thenextweb.com/news/kupando-series-a-kup101-phase-1b-innate-immunityTags:#technology#the-next-web
Found this useful? Share it!
Read the Full Story
Continue reading on The Next Web
Related Stories
💻
💻Technology
British cryptographer Adam Back denies NYT report that he is Bitcoin creator Satoshi Nakamoto
about 7 hours ago

💻Technology
Amazon’s Smart Thermostat can help lower your energy bills, and it’s down to $62
about 7 hours ago
💻Technology
Greece will ban all kids under 15 from using social media
about 7 hours ago
💻
💻Technology
Hackers steal and leak sensitive LAPD police documents
about 7 hours ago
